Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fayong Luo is active.

Publication


Featured researches published by Fayong Luo.


Journal of Immunology | 2014

Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis

T. Le Thanh-Thuy; Harry Karmouty-Quintana; Ernestina Melicoff; T. Le Thanh-Truc; Tingting Weng; Ning Yuan Chen; Mesias Pedroza; Yang Zhou; Jonathan Davies; Kemly Philip; Jose G. Molina; Fayong Luo; Anuh T. George; Luis J. Garcia-Morales; Raquel R. Bunge; Brian A. Bruckner; Matthias Loebe; Harish Seethamraju; Sandeep K. Agarwal; Michael R. Blackburn

Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with progressive fibrosis and death within 2–3 y of diagnosis. IPF incidence and prevalence rates are increasing annually with few effective treatments available. Inhibition of IL-6 results in the attenuation of pulmonary fibrosis in mice. It is unclear whether this is due to blockade of classical signaling, mediated by membrane-bound IL-6Rα, or trans signaling, mediated by soluble IL-6Rα (sIL-6Rα). Our study assessed the role of sIL-6Rα in IPF. We demonstrated elevations of sIL-6Rα in IPF patients and in mice during the onset and progression of fibrosis. We demonstrated that protease-mediated cleavage from lung macrophages was important in production of sIL-6Rα. In vivo neutralization of sIL-6Rα attenuated pulmonary fibrosis in mice as seen by reductions in myofibroblasts, fibronectin, and collagen in the lung. In vitro activation of IL-6 trans signaling enhanced fibroblast proliferation and extracellular matrix protein production, effects relevant in the progression of pulmonary fibrosis. Taken together, these findings demonstrate that the production of sIL-6Rα from macrophages in the diseased lung contributes to IL-6 trans signaling that in turn influences events crucial in pulmonary fibrosis.


Circulation | 2016

Beneficial role of erythrocyte adenosine A2B receptor-mediated AMP-activated protein kinase activation in high-altitude hypoxia

Hong Liu; Yujin Zhang; Hongyu Wu; Angelo D’Alessandro; Gennady G. Yegutkin; Anren Song; Kaiqi Sun; Jessica Li; Ning-Yuan Cheng; Aji Huang; Yuan Edward Wen; Ting Ting Weng; Fayong Luo; Travis Nemkov; Hong Sun; Rodney E. Kellems; Harry Karmouty-Quintana; Kirk C. Hansen; Bihong Zhao; Andrew W. Subudhi; Sonja Jameson-Van Houten; Colleen G. Julian; Andrew T. Lovering; Holger K. Eltzschig; Michael R. Blackburn; Robert C. Roach; Yang Xia

Background: High altitude is a challenging condition caused by insufficient oxygen supply. Inability to adjust to hypoxia may lead to pulmonary edema, stroke, cardiovascular dysfunction, and even death. Thus, understanding the molecular basis of adaptation to high altitude may reveal novel therapeutics to counteract the detrimental consequences of hypoxia. Methods: Using high-throughput, unbiased metabolomic profiling, we report that the metabolic pathway responsible for production of erythrocyte 2,3-bisphosphoglycerate (2,3-BPG), a negative allosteric regulator of hemoglobin-O2 binding affinity, was significantly induced in 21 healthy humans within 2 hours of arrival at 5260 m and further increased after 16 days at 5260 m. Results: This finding led us to discover that plasma adenosine concentrations and soluble CD73 activity rapidly increased at high altitude and were associated with elevated erythrocyte 2,3-BPG levels and O2 releasing capacity. Mouse genetic studies demonstrated that elevated CD73 contributed to hypoxia-induced adenosine accumulation and that elevated adenosine-mediated erythrocyte A2B adenosine receptor activation was beneficial by inducing 2,3-BPG production and triggering O2 release to prevent multiple tissue hypoxia, inflammation, and pulmonary vascular leakage. Mechanistically, we demonstrated that erythrocyte AMP-activated protein kinase was activated in humans at high altitude and that AMP-activated protein kinase is a key protein functioning downstream of the A2B adenosine receptor, phosphorylating and activating BPG mutase and thus inducing 2,3-BPG production and O2 release from erythrocytes. Significantly, preclinical studies demonstrated that activation of AMP-activated protein kinase enhanced BPG mutase activation, 2,3-BPG production, and O2 release capacity in CD73-deficient mice, in erythrocyte-specific A2B adenosine receptor knockouts, and in wild-type mice and in turn reduced tissue hypoxia and inflammation. Conclusions: Together, human and mouse studies reveal novel mechanisms of hypoxia adaptation and potential therapeutic approaches for counteracting hypoxia-induced tissue damage.


The FASEB Journal | 2015

Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension

Harry Karmouty-Quintana; Kemly Philip; Luis F. Acero; Ning Yuan Chen; Tingting Weng; Jose G. Molina; Fayong Luo; Jonathan Davies; Ngoc Bao Le; Isabelle Bunge; Kelly A. Volcik; Thanh Thuy T Le; Yang Xia; Holger K. Eltzschig; Michael R. Blackburn

Idiopathic pulmonary fibrosis (IPF) is a lethal, fibroproliferative disease. Pulmonary hypertension (PH) can develop secondary to IPF and increase mortality. Alternatively, activated macrophages (AAMs) contribute to the pathogenesis of both IPF and PH. Here we hypothesized that adenosine signaling through the ADORA2B on AAMs impacts the progression of these disorders and that conditional deletion of ADORA2B on myeloid cells would have a beneficial effect in a model of these diseases. Conditional knockout mice lacking ADORA2B on myeloid cells (Adora2Bf/f‐LysMCre) were exposed to the fibrotic agent bleomycin (BLM; 0.035 U/g body weight, i.p.). At 14, 17, 21, 25, or 33 d after exposure, SpO2, bronchoalveolar lavage fluid (BALF), and histologic analyses were performed. On day 33, lung function and cardiovascular analyses were determined. Markers for AAM and mediators of fibrosis and PH were assessed. Adora2Bf/f‐LysMCre mice presented with attenuated fibrosis, improved lung function, and no evidence of PH compared with control mice exposed to BLM. These findings were accompanied by reduced expression of CD206 and arginase‐1, markers for AAMs. A 10‐fold reduction in IL‐6 and a 5‐fold decrease in hyaluronan, both linked to lung fibrosis and PH, were also observed. These data suggest that activation of the ADORA2B on macrophages plays an active role in the pathogenesis of lung fibrosis and PH.‐Karmouty‐Quintana, H., Philip, K., Acero, L. F., Chen, N.‐Y., Weng, T., Molina, J. G., Luo, F., Davies, J., Le, N.‐B., Bunge, I., Volcik, K. A., Le, T.‐T. T., Johnston, R. A., Xia, Y., Eltzschig, H. K., Blackburn, M. R. Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB J. 29, 50–60 (2015). www.fasebj.org


American Journal of Respiratory and Critical Care Medicine | 2014

Hypoxia-induced deoxycytidine kinase contributes to epithelial proliferation in pulmonary fibrosis.

Tingting Weng; Jens M. Poth; Harry Karmouty-Quintana; Luis J. Garcia-Morales; Ernestina Melicoff; Fayong Luo; Ning Yuan Chen; Christopher M. Evans; Raquel R. Bunge; Brian A. Bruckner; Matthias Loebe; Kelly A. Volcik; Holger K. Eltzschig; Michael R. Blackburn

RATIONALE Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease with few therapeutic options. Apoptosis of alveolar epithelial cells, followed by abnormal tissue repair characterized by hyperplastic epithelial cell formation, is a pathogenic process that contributes to the progression of pulmonary fibrosis. However, the signaling pathways responsible for increased proliferation of epithelial cells remain poorly understood. OBJECTIVES To investigate the role of deoxycytidine kinase (DCK), an important enzyme for the salvage of deoxynucleotides, in the progression of pulmonary fibrosis. METHODS DCK expression was examined in the lungs of patients with IPF and mice exposed to bleomycin. The regulation of DCK expression by hypoxia was studied in vitro and the importance of DCK in experimental pulmonary fibrosis was examined using a DCK inhibitor and alveolar epithelial cell-specific knockout mice. MEASUREMENTS AND MAIN RESULTS DCK was elevated in hyperplastic alveolar epithelial cells of patients with IPF and in mice exposed to bleomycin. Increased DCK was localized to cells associated with hypoxia, and hypoxia directly induced DCK in alveolar epithelial cells in vitro. Hypoxia-induced DCK expression was abolished by silencing hypoxia-inducible factor 1α and treatment of bleomycin-exposed mice with a DCK inhibitor attenuated pulmonary fibrosis in association with decreased epithelial cell proliferation. Furthermore, DCK expression, and proliferation of epithelial cells and pulmonary fibrosis was attenuated in mice with conditional deletion of hypoxia-inducible factor 1α in the alveolar epithelium. CONCLUSIONS Our findings suggest that the induction of DCK after hypoxia plays a role in the progression of pulmonary fibrosis by contributing to alveolar epithelial cell proliferation.


Journal of Experimental Medicine | 2017

Resetting microbiota by Lactobacillus reuteri inhibits T reg deficiency–induced autoimmunity via adenosine A2A receptors

Baokun He; Thomas K. Hoang; Ting Wang; Michael J. Ferris; Christopher M. Taylor; Xiangjun Tian; Meng Luo; Dat Q. Tran; Jain Zhou; Nina Tatevian; Fayong Luo; Jose G. Molina; Michael R. Blackburn; Thomas H. Gomez; Stefan Roos; J. Marc Rhoads; Yuying Liu

Regulatory T (T reg) cell deficiency causes lethal, CD4+ T cell–driven autoimmune diseases. Stem cell transplantation is used to treat these diseases, but this procedure is limited by the availability of a suitable donor. The intestinal microbiota drives host immune homeostasis by regulating the differentiation and expansion of T reg, Th1, and Th2 cells. It is currently unclear if T reg cell deficiency–mediated autoimmune disorders can be treated by targeting the enteric microbiota. Here, we demonstrate that Foxp3+ T reg cell deficiency results in gut microbial dysbiosis and autoimmunity over the lifespan of scurfy (SF) mouse. Remodeling microbiota with Lactobacillus reuteri prolonged survival and reduced multiorgan inflammation in SF mice. L. reuteri changed the metabolomic profile disrupted by T reg cell deficiency, and a major effect was to restore levels of the purine metabolite inosine. Feeding inosine itself prolonged life and inhibited multiorgan inflammation by reducing Th1/Th2 cells and their associated cytokines. Mechanistically, the inhibition of inosine on the differentiation of Th1 and Th2 cells in vitro depended on adenosine A2A receptors, which were also required for the efficacy of inosine and of L. reuteri in vivo. These results reveal that the microbiota–inosine–A2A receptor axis might represent a potential avenue for combatting autoimmune diseases mediated by T reg cell dysfunction.


Physiological Reports | 2014

Adenosine promotes vascular barrier function in hyperoxic lung injury

Jonathan Davies; Harry Karmouty-Quintana; Thuy T. Le; Ning Yuan Chen; Tingting Weng; Fayong Luo; Jose G. Molina; Bhagavatula Moorthy; Michael R. Blackburn

Hyperoxic lung injury is characterized by cellular damage from high oxygen concentrations that lead to an inflammatory response in the lung with cellular infiltration and pulmonary edema. Adenosine is a signaling molecule that is generated extracellularly by CD73 in response to injury. Extracellular adenosine signals through cell surface receptors and has been found to be elevated and plays a protective role in acute injury situations. In particular, ADORA2B activation is protective in acute lung injury. However, little is known about the role of adenosine signaling in hyperoxic lung injury. We hypothesized that hyperoxia‐induced lung injury leads to CD73‐mediated increases in extracellular adenosine, which is protective through ADORA2B signaling pathways. To test this hypothesis, we exposed C57BL6, CD73−/−, and Adora2B−/− mice to 95% oxygen or room air and examined markers of pulmonary inflammation, edema, and monitored lung histology. Hyperoxic exposure caused pulmonary inflammation and edema in association with elevations in lung adenosine levels. Loss of CD73‐mediated extracellular adenosine production exacerbated pulmonary edema without affecting inflammatory cell counts. Furthermore, loss of the ADORA2B had similar results with worsening of pulmonary edema following hyperoxia exposure without affecting inflammatory cell infiltration. This loss of barrier function correlated with a decrease in occludin in pulmonary vasculature in CD73−/− and Adora2B−/− mice following hyperoxia exposure. These results demonstrate that exposure to a hyperoxic environment causes lung injury associated with an increase in adenosine concentration, and elevated adenosine levels protect vascular barrier function in hyperoxic lung injury through the ADORA2B‐dependent regulation of occludin.


The FASEB Journal | 2016

Extracellular adenosine levels are associated with the progression and exacerbation of pulmonary fibrosis.

Fayong Luo; Ngoc Bao Le; Tingting Mills; Ning Yuan Chen; Harry Karmouty-Quintana; Jose G. Molina; Jonathan Davies; Kemly Philip; Kelly A. Volcik; Hong Liu; Yang Xia; Holger K. Eltzschig; Michael R. Blackburn

Idiopathic pulmonary fibrosis is a devastating lung disease with limited treatment options. The signaling molecule adenosine is produced in response to injury and serves a protective role in early stages of injury and is detrimental during chronic stages of disease such as seen in lung conditions such as pulmonary fibrosis. Understanding the association of extracellular adenosine levels and the progression of pulmonary fibrosis is critical for designing adenosine based approaches to treat pulmonary fibrosis. The goal of this study was to use various models of experimental lung fibrosis to understand when adenosine levels are elevated during pulmonary fibrosis and whether these elevations were associated with disease progression and severity. To accomplish this, extracellular adenosine levels, defined as adenosine levels found in bronchio‐alveolar lavage fluid, were determined in mouse models of resolvable and progressive pulmonary fibrosis. We found that relative bronchioalveolar lavage fluid adenosine levels are progressively elevated in association with pulmonary fibrosis and that adenosine levels diminish in association with the resolution of lung fibrosis. In addition, treatment of these models with dipyridamole, an inhibitor of nucleoside transporters that potentiates extracellular adenosine levels, demonstrated that the resolution of lung fibrosis is blocked by the failure of adenosine levels to subside. Furthermore, exacerbating adenosine levels led to worse fibrosis in a progressive fibrosis model. Increased adenosine levels were associated with elevation of IL‐6 and IL‐17, which are important inflammatory cytokines in pulmonary fibrosis. These results demonstrate that extracellular adenosine levels are closely associated with the progression of experimental pulmonary fibrosis and that this signaling pathway may mediate fibrosis by regulating IL‐6 and IL‐17 production.—Luo, F., Le, N.‐B., Mills, T., Chen, N.‐Y., Karmouty‐Quintana, H., Molina, J. G., Davies, J., Philip, K., Volcik, K. A., Liu, H., Xia, Y., Eltzschig, H. K., Blackburn, M. R. Extracellular adenosine levels are associated with the progression and exacerbation of pulmonary fibrosis. FASEB J. 30, 874–883 (2016). www.fasebj.org


American Journal of Physiology-lung Cellular and Molecular Physiology | 2016

Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension.

Ning Yuan Chen; Scott D. Collum; Fayong Luo; Tingting Weng; Thuy T. Le; Adriana M. Hernandez; Kemly Philip; Jose G. Molina; Luis J. Garcia-Morales; Yanna Cao; Tien C. Ko; Javier Amione-Guerra; Odeaa Aljabbari; Raquel R. Bunge; Keith A. Youker; Brian A. Bruckner; Rizwan Hamid; Jonathan Davies; N. Sinha; Harry Karmouty-Quintana

Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology. The development of pulmonary hypertension (PH) is considered the single most significant predictor of mortality in patients with chronic lung diseases. The processes that govern the progression and development of fibroproliferative and vascular lesions in IPF are not fully understood. Using human lung explant samples from patients with IPF with or without a diagnosis of PH as well as normal control tissue, we report reduced BMPR2 expression in patients with IPF or IPF+PH. These changes were consistent with dampened P-SMAD 1/5/8 and elevated P-SMAD 2/3, demonstrating reduced BMPR2 signaling and elevated TGF-β activity in IPF. In the bleomycin (BLM) model of lung fibrosis and PH, we also report decreased BMPR2 expression compared with control animals that correlated with vascular remodeling and PH. We show that genetic abrogation or pharmacological inhibition of interleukin-6 leads to diminished markers of fibrosis and PH consistent with elevated levels of BMPR2 and reduced levels of a collection of microRNAs (miRs) that are able to degrade BMPR2. We also demonstrate that isolated bone marrow-derived macrophages from BLM-exposed mice show reduced BMPR2 levels upon exposure with IL6 or the IL6+IL6R complex that are consistent with immunohistochemistry showing reduced BMPR2 in CD206 expressing macrophages from lung sections from IPF and IPF+PH patients. In conclusion, our data suggest that depletion of BMPR2 mediated by a collection of miRs induced by IL6 and subsequent STAT3 phosphorylation as a novel mechanism participating to fibroproliferative and vascular injuries in IPF.


The FASEB Journal | 2017

HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis

Kemly Philip; Tingting Mills; Jonathan Davies; Ning Yuan Chen; Harry Karmouty-Quintana; Fayong Luo; Jose G. Molina; Javier Amione-Guerra; N. Sinha; Ashrith Guha; Holger K. Eltzschig; Michael R. Blackburn

Idiopathic pulmonary fibrosis (IPF) is a deadly chronic lung disease. Extracellular accumulation of adenosine and subsequent activation of the ADORA2B receptor play important roles in regulating inflammation and fibrosis in IPF. Additionally, alternatively activated macrophages (AAMs) expressing ADORA2B have been implicated in mediating adenosine’s effects in IPF. Although hypoxic conditions are present in IPF, hypoxia’s role as a direct modulator of macrophage phenotype and identification of factors that regulate ADORA2B expression on AAMs in IPF is not well understood. In this study, an experimental mouse model of pulmonary fibrosis and lung samples from patients with IPF were used to examine the effects and interactions of macrophage differentiation and hypoxia on fibrosis. We demonstrate that hypoxia‐inducible factor 1‐α (HIF1A) inhibition in late stages of bleomycin‐induced injury attenuates pulmonary fibrosis in association, with reductions in ADORA2B expression in AAMs. Additionally, ADORA2B deletion or pharmacological antagonism along with HIF1A inhibition disrupts AAM differentiation and subsequent IL‐6 production in cultured macrophages. These findings suggest that hypoxia, through HIF1A, contributes to the development and progression of pulmonary fibrosis through its regulation of ADORA2B expression on AAMs, cell differentiation, and production of profibrotic mediators. These studies support a potential role for HIF1A or ADORA2B antagonists in the treatment of IPF.—Philip, K., Mills, T. W., Davies, J., Chen, N.‐Y., Karmouty‐Quintana, H., Luo, F., Molina, J. G., Amione‐Guerra, J., Sinha, N., Guha, A., Eltzschig, H. K., Blackburn, M. R. HIF1A up‐regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis. FASEB J. 31, 4745–4758 (2017). www.fasebj.org


American Journal of Respiratory Cell and Molecular Biology | 2016

Altered Hypoxic–Adenosine Axis and Metabolism in Group III Pulmonary Hypertension

Luis J. Garcia-Morales; Ning Yuan Chen; Tingting Weng; Fayong Luo; Jonathan Davies; Kemly Philip; Kelly A. Volcik; Ernestina Melicoff; Javier Amione-Guerra; Raquel R. Bunge; Brian A. Bruckner; Matthias Loebe; Holger K. Eltzschig; Lavannya M. Pandit; Michael R. Blackburn; Harry Karmouty-Quintana

Group III pulmonary hypertension (PH) is a highly prevalent and deadly lung disorder with limited treatment options other than transplantation. Group III PH affects patients with ongoing chronic lung injury, such as idiopathic pulmonary fibrosis (IPF). Between 30 and 40% of patients with IPF are diagnosed with PH. The diagnosis of PH has devastating consequences to these patients, leading to increased morbidity and mortality, yet the molecular mechanisms involved in the development of PH in patients with chronic lung disease remain elusive. Our hypothesis was that the hypoxic-adenosinergic system is enhanced in patients with group III PH compared with patients with IPF with no PH. Explanted lung tissue was analyzed for markers of the hypoxic-adenosine axis, including expression levels of hypoxia-inducible factor (HIF)-1A, adenosine A2B receptor, CD73, and equilibrative nucleotide transporter-1. In addition, we assessed whether altered mitochondrial metabolism was present in these samples. Increased expression of HIF-1A was observed in tissues from patients with group III PH. These changes were consistent with increased evidence of adenosine accumulation in group III PH. A novel observation of our study was of evidence suggesting altered mitochondrial metabolism in lung tissue from group III PH leading to increased succinate levels that are able to further stabilize HIF-1A. Our data demonstrate that the hypoxic-adenosine axis is up-regulated in group III PH and that subsequent succinate accumulation may play a part in the development of group III PH.

Collaboration


Dive into the Fayong Luo's collaboration.

Top Co-Authors

Avatar

Harry Karmouty-Quintana

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Michael R. Blackburn

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Ning Yuan Chen

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Jonathan Davies

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Jose G. Molina

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Tingting Weng

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Holger K. Eltzschig

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Kemly Philip

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Brian A. Bruckner

Houston Methodist Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge